Title: Navigating the Genetic Complexities of Lung Cancer: Case Studies in Germline Variants and Resistance Mutations

September 24, 2024

11:00am-12:00pm ET

Description

We will delve into the intricate genetic landscape of lung cancer through the analysis of four compelling cases. Two of these cases involve patients harboring germline variants alongside critical driver mutations, showcasing the complex interplay between inherited and acquired genetic factors in lung cancer. The other two cases present the challenge of managing EGFR-mutated lung cancer with secondary T790M, further complicated by the emergence of cis and trans C797S resistance mutations. These cases highlight the necessity for dynamic and personalized treatment approaches, emphasizing the importance of genetic profiling in guiding therapeutic decisions and improving patient outcomes.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentation followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

• Discuss the Impact of Germline Variants in Lung Cancer: Discuss how these inherited genetic factors can influence treatment decisions and patient outcomes.
• Apply Acquired Resistance Mutations in EGFR-Mutated Lung Cancer: Evaluate the challenges these mutations present in clinical management and the strategies to overcome them.
• Outline the importance of comprehensive genetic profiling.

Beth Pitel, M.S. Clinical Variant Scientist Assistant Professor of Laboratory Medicine and Pathology Division of Laboratory Genetics and Genomics Mayo Clinic, Rochester MN

Moushumi Suryavanshi, M.D., Ph.D., FRCPath Associate Professor & Head, Molecular Biology Amrita Institute of Medical Sciences & Research Centre Faridabad, India Dr. Moushumi Suryavanshi is a distinguished molecular biologist and clinical scientist with extensive expertise in molecular genetic technologies. She has played a pivotal role in the implementation and utilization of liquid biopsy and next-generation sequencing (NGS) for cancer testing in clinical practice across India. Her contributions have significantly advanced the field, ensuring precise and personalized cancer diagnostics. As a leader in molecular pathology, Dr. Suryavanshi continues to drive innovation and excellence in molecular biology and oncology research.

Prashant Mehta, DM Senior Consultant and Program Director Lymphoid Neoplasms, Cell Therapy, Lung Cancer  Dept. of Haematology, Medical Oncology and BMT Amrita Institute of Medical Sciences & Research Centre Faridabad, India Dr. Mehta, Senior Consultant and Program Director for Lymphoid Neoplasms, Cell Therapy, and Lung Cancer at Amrita Hospital, Faridabad, is an accomplished oncologist with a DM in Medical Oncology from AIIMS, Delhi. A member of the Indian Cooperative Oncology Network (ICON) and several prestigious oncology societies, he has over 50 publications and has led more than 20 clinical trials. He received the ICMR research grant for cervical cancer immunotherapy and established the first CAR T-cell therapy program in Northern India. Dr. Mehta also holds fellowships and editorial positions and has been recognized for his contributions to oncology education and research.

Vidit Kapoor, DM Consultant Dept. of Hematology, Medical Oncology and BMT Amrita Institute of Medical Sciences & Research Centre Faridabad, India   Dr. Kapoor is an American Board-certified Medical Oncologist and Consultant, specializing in Solid Organ Oncology and Palliative Medicine. He also serves on the editorial board of the International Journal of Molecular and Immuno Oncology (IJMIO).

Planning Committee:

Beth Pitel, MS, CG(ASCP)

Gordana Raca, MD, PhD, FACMG

Manuela Benary, PhD

Jason Saliba, PhD

Jane Radford, MHA, CHCP

Claudia Barnett 

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days of the date of the activity. Educational credit requests after this date will not be accepted.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.

Questions regarding CE credit should be directed to education@acmg.net